-
Autor
Egyed, Miklos 1 Gerds, Aaron T 1 Grosicki, Sebastian 1 Gupta, Vikas 1 Harrison, Claire N 1 Huang, Mei 1 Illés, Árpád 1 Kawashima, Jun 1 Kiladjian, Jean-Jacques 1 Kirgner, Ilya 1 Klencke, Barbara 1 Mayer, Jiří 1 McLornan, Donal 1 Mesa, Ruben 1 Oh, Stephen T 1 Platzbecker, Uwe 1 Vannucchi, Alessandro M 1 Verstovsek, Srdan 1 Woźny, Tomasz 1 Yoon, Sung-Soo 1
-
Pracoviště
Atrium Health Wake Forest Baptist Com... 1 Cancer Research Institute Seoul Natio... 1 Center for Medical Innovation Biomedi... 1 Cleveland Clinic Taussig Cancer Insti... 1 Clinic of Hematology Cellular Therapy... 1 Department of Experimental and Clinic... 1 Department of Hematology Faculty of M... 1 Department of Hematology Szpital MSWi... 1 Department of Hematology and Cancer P... 1 Department of Internal Medicine Haema... 1 Department of Internal Medicine Seoul... 1 Department of Medicine and Department... 1 Guy's and St Thomas' NHS Foundation T... 1 Guy's and St Thomas' NHS Foundation T... 1 Hematology Institute Tel Aviv Sourask... 1 Princess Margaret Cancer Center Unive... 1 Sierra Oncology a GSK company San Mat... 1 Teaching Hospital Mór Kaposi Kaposvár... 1 The Sackler Faculty of Medicine Tel A... 1 The University of Texas MD Anderson C... 1
- Formát
- Publikační typ
- Kategorie
- Jazyk
- Země
- Časopis/zdroj
- Dostupnost
- Vlastník
-
Autor
Egyed, Miklos 1 Gerds, Aaron T 1 Grosicki, Sebastian 1 Gupta, Vikas 1 Harrison, Claire N 1 Huang, Mei 1 Illés, Árpád 1 Kawashima, Jun 1 Kiladjian, Jean-Jacques 1 Kirgner, Ilya 1 Klencke, Barbara 1 Mayer, Jiří 1 McLornan, Donal 1 Mesa, Ruben 1 Oh, Stephen T 1 Platzbecker, Uwe 1 Vannucchi, Alessandro M 1 Verstovsek, Srdan 1 Woźny, Tomasz 1 Yoon, Sung-Soo 1
-
Pracoviště
Atrium Health Wake Forest Baptist Com... 1 Cancer Research Institute Seoul Natio... 1 Center for Medical Innovation Biomedi... 1 Cleveland Clinic Taussig Cancer Insti... 1 Clinic of Hematology Cellular Therapy... 1 Department of Experimental and Clinic... 1 Department of Hematology Faculty of M... 1 Department of Hematology Szpital MSWi... 1 Department of Hematology and Cancer P... 1 Department of Internal Medicine Haema... 1 Department of Internal Medicine Seoul... 1 Department of Medicine and Department... 1 Guy's and St Thomas' NHS Foundation T... 1 Guy's and St Thomas' NHS Foundation T... 1 Hematology Institute Tel Aviv Sourask... 1 Princess Margaret Cancer Center Unive... 1 Sierra Oncology a GSK company San Mat... 1 Teaching Hospital Mór Kaposi Kaposvár... 1 The Sackler Faculty of Medicine Tel A... 1 The University of Texas MD Anderson C... 1
- Formát
- Publikační typ
- Kategorie
- Jazyk
- Země
- Časopis/zdroj
- Dostupnost
- Vlastník
NLK
Directory of Open Access Journals
od 2018
PubMed Central
od 2017
Europe PubMed Central
od 2017
Wiley-Blackwell Open Access Titles
od 1997
PubMed
37908862
DOI
10.1097/hs9.0000000000000963
Knihovny.cz E-zdroje
The oral activin A receptor type I, Janus kinase 1 (JAK1), and JAK2 inhibitor momelotinib demonstrated symptom, spleen, and anemia benefits in intermediate- and high-risk myelofibrosis (MF). Post hoc analyses herein evaluated the efficacy and safety of momelotinib in patients with MF and thrombocytopenia (platelet counts <100 × 109/L) from randomized phase 3 studies: MOMENTUM (momelotinib versus danazol; JAK inhibitor experienced); SIMPLIFY-1 (momelotinib versus ruxolitinib; JAK inhibitor naïve); and SIMPLIFY-2 (momelotinib versus best available therapy; JAK inhibitor experienced); these studies were not statistically powered to assess differences in thrombocytopenic subgroups, and these analyses are descriptive. The treatment effect of momelotinib versus ruxolitinib on week 24 response rates (spleen volume reduction ≥35%/Total Symptom Score reduction ≥50%/transfusion independence) was numerically comparable or better in thrombocytopenic patients versus the overall JAK inhibitor naive population; rates were preserved with momelotinib in thrombocytopenic patients but attenuated with ruxolitinib (momelotinib: 27%/28%/67% overall versus 39%/35%/61% in thrombocytopenic group; ruxolitinib: 29%/42%/49% overall versus 0%/22%/39% in thrombocytopenic group, respectively). In contrast to ruxolitinib, momelotinib maintained high dose intensity throughout the treatment. In the JAK inhibitor experienced population, thrombocytopenic patients had the following: (1) numerically higher symptom and transfusion independence response rates with momelotinib than in control arms; and (2) preserved spleen, symptom, and transfusion independence response rates with momelotinib relative to the overall study populations. The safety profile of momelotinib in thrombocytopenic patients was also consistent with the overall study population. In summary, momelotinib represents a safe and effective treatment option for patients with MF and moderate-to-severe thrombocytopenia.
- Publikační typ
- časopisecké články MeSH
Upřesnit dle MeSH
Sdílet
Název dokumentu
Po ukončení testovacího provozu bude odkaz přesměrován adresu produkční verze portálu Medvik.